|
US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
WO1993017668A1
(en)
|
1992-03-12 |
1993-09-16 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release acth containing microspheres
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
ATE370961T1
(de)
|
1998-05-06 |
2007-09-15 |
Genentech Inc |
Reinigung von antikörpern durch ionenaustauschchromatographie
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
EP1542723B1
(en)
|
2002-08-16 |
2011-02-23 |
ImmunoGen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
UA90480C2
(uk)
|
2004-07-22 |
2010-05-11 |
Джэнэнтэк, Инк. |
Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
NZ587706A
(en)
|
2008-03-18 |
2012-12-21 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
HUE044352T2
(hu)
*
|
2011-10-14 |
2019-10-28 |
Hoffmann La Roche |
Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
|
|
KR102000312B1
(ko)
|
2011-10-14 |
2019-07-15 |
어레이 바이오파마 인크. |
Erb2 (her2) 저해제의 고체 분산물
|
|
US9168254B2
(en)
|
2011-10-14 |
2015-10-27 |
Array Biopharma Inc. |
Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
EP3964237B1
(en)
|
2013-03-15 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
WO2014200891A1
(en)
|
2013-06-11 |
2014-12-18 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES |
Her2-specific monoclonal antibodies and conjugates thereof
|
|
AU2014311361B2
(en)
|
2013-08-26 |
2018-11-29 |
Regeneron Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
|
|
PT3480215T
(pt)
|
2013-11-19 |
2021-07-05 |
Remegen Ltd |
Anticorpo anti-her2 e seu conjugado
|
|
UA118113C2
(uk)
|
2013-12-16 |
2018-11-26 |
Дженентек, Інк. |
Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
|
|
WO2015104373A2
(en)
|
2014-01-10 |
2015-07-16 |
Synthon Biopharmaceuticals B.V. |
Duocarmycin adcs for use in treatment of endometrial cancer
|
|
SG11201603960XA
(en)
|
2014-01-31 |
2016-07-28 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugate
|
|
CA2943299A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
|
CA2978340C
(en)
|
2015-03-27 |
2024-05-28 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
MX390630B
(es)
|
2016-01-25 |
2025-03-21 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
|
|
WO2018066626A1
(ja)
|
2016-10-07 |
2018-04-12 |
第一三共株式会社 |
抗her2抗体-薬物コンジュゲート投与による耐性癌の治療
|
|
EP3615067A1
(en)
*
|
2017-04-28 |
2020-03-04 |
Seattle Genetics, Inc. |
Treatment of her2 positive cancers
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Her2及び/またはaplp2に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|